AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$HIMS

Chi Michael sold $442K of HIMS

Chi Michael (Chief Operating Officer) sold 14,027 shares of Hims & Hers Health, Inc. (HIMS) at $31.50 ($0.44M total) on 2026-06-17 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chi Michael
Published Jun 17, 2026, 10:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 10:52 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$HIMS
Neutral
medium confidence
Mentioned
$HIMS
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HIMSNeutralLow
01

Why it matters

The only new information is the COO’s scheduled open-market sale details (shares, price, total value) under a 10b5-1 plan; no business or financial guidance changes are provided.

02

Market read

This is a routine insider-sale filing; it may slightly influence sentiment but lacks fundamental catalysts.

03

What to watch

Traders may over-weight insider sales; without accompanying buys, guidance changes, or operational news, the signal is usually weak.

Relevance 3/10Novelty 6/10Timing: SEC Form 4 filed today (2026-06-17)

Background

The article is an SEC Form 4 insider transaction disclosure for Hims & Hers Health, Inc.

Company-level read

Ticker impact

$HIMSNeutralMedium confidence
Context

Hims & Hers Health COO Chi Michael sold 14,027 shares in an open-market transaction at $31.50 on a 10b5-1 plan filed today.

Expected impact

Likely limited/short-lived impact; any move would be small unless accompanied by other catalysts.

Evidence & confidence

The filing is a primary-source Form 4, but the article provides no new fundamentals—only a scheduled insider sale size and price.

Market effects

Sector

Minimal; routine insider sale does not change sector fundamentals.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • public_company
    Hims & Hers Health, Inc.

    Issuer of the Form 4 insider sale by COO Chi Michael.

  • insider
    Chi Michael

    Chief Operating Officer who sold 14,027 shares at $31.50 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

HIMS insider trading history →

Related articles

$HIMSHighAI 8/10

Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses “Enforcement Discretion” to Open Peptide Compounding

Hims & Hers Health (HIMS) shares rose 6% after HHS announced enforcement discretion for six peptides, potentially benefiting Hims' peptide facility. The company awaits final FDA rules for a full launch. Hims' gross margin fell to 63.8% in Q2, with Q3 results on Nov. 9. Analysts estimate the peptide market at $2.2B-$3.3B, and Hims' revenue at $4.49B by 2028.

finance.yahoo.com
$HIMSMed

Hims Seeks Dismissal of FTC Suit Over User Data, Subscriptions

Hims & Hers Health Inc. asked a California judge to dismiss an FTC lawsuit alleging deceptive practices, improper data sharing, and difficult subscription cancellations. The company claims its privacy policy is clear and the FTC misapplied federal law. The FTC argues Hims violated a 2010 law requiring clear disclosure of subscription terms. Hims has 2.6 million subscribers. A hearing is scheduled for January 7.

claimsjournal.com